Related Experiment Video

Updated: Dec 30, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.2K

10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and

Goran Petrovski1, Fawziya Al Khalaf2, Judith Campbell2

  • 1Division of Endocrinology and Diabetes, Department of Pediatric Medicine, Sidra Medicine, HB 6E 219, Al Luqta Street, Education City North Campus, PO Box 26999, Doha, Qatar. gpetrovski@sidra.org.

Acta Diabetologica
|January 19, 2020
PubMed

Insights

The 10-day initiation protocol for the MiniMed 670G hybrid closed-loop (HCL) system effectively improved glycemic control in children with type 1 diabetes on multiple daily injections (MDI). This concise protocol led to significant reductions in HbA1c and increased time in range without severe hypoglycemia.

Area of Science:

  • Endocrinology
  • Pediatric Diabetes Management
  • Medical Device Technology

Background:

  • Type 1 diabetes (T1D) management in children on multiple daily injections (MDI) often presents challenges in achieving optimal glycemic control.
  • Hybrid closed-loop (HCL) systems offer a potential solution, but efficient initiation protocols are crucial for successful adoption.

Purpose of the Study:

  • To evaluate the efficacy of a structured 10-day initiation protocol for the MiniMed 670G HCL system in pediatric T1D patients previously on MDI.
  • To assess the system's ability to achieve desirable glycemic control within this short initiation period.

Main Methods:

  • An open-label, single-arm study involving 30 children (aged 7-18 years) with T1D on MDI.
  • A 10-day protocol included system assessment, training, Manual Mode use, and transition to Auto Mode.
  • Participants used the HCL system for 84 days in Auto Mode.

Main Results:

  • Mean HbA1c decreased significantly from 8.2% at baseline to 6.7% after 84 days in Auto Mode (p=0.017).
  • Time in glycemic range (70-180 mg/dL) increased from 46.9% to 75.6% (p<0.001).
  • No severe hypoglycemia or diabetic ketoacidosis (DKA) events were reported.

Conclusions:

  • The 10-day initiation protocol for the MiniMed 670G HCL system is effective for children and adolescents with T1D transitioning from MDI.
  • This concise protocol facilitates successful adoption of HCL technology, leading to improved glycemic outcomes.
Abstract

Keywords:
Hybrid closed-loop systemMultiple daily injectionProtocolType 1 diabetes

More Related Videos

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

17.2K
Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING07:36

Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG hOMING

Published on: March 14, 2019

7.4K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
605
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
569
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.7K
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.1K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
792
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
1.9K